References
- Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297.
- Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
- Afra TP, Razmi TM, Dogra S. Apremilast in psoriasis and beyond: big hopes on a small molecule. Indian Dermatol Online J. 2019;10(1):1–12.
- Wyden-Grassley Sovaldi Investigation Finds Revenue-Driven Pricing Strategy Behind $84,000 Hepatitis Drug The United States Senate Committee on Finance. [cited 2020 Oct 4]. Available from: https://www.finance.senate.gov/ranking-members-news/wyden-grassley-sovaldi-investigation-finds-revenue-driven-pricing-strategy-behind-84-000-hepatitis-drug
- Goldberg EL, Dekoven M, Schabert VF, et al. Patient medication adherence: the forgotten aspect of biologics. Biotechnol Healthc. 2009;6(2):39–44.
- Singh P, Silverberg JI. Growth in the cost of biologics in Medicare beneficiaries, 2013 to 2016. J Am Acad Dermatol. 2019;80(1):281–282.
- Erath A, Dusetzina SB. Assessment of expected out-of-pocket spending for rheumatoid arthritis biologics among patients enrolled in medicare part D, 2010–2019. JAMA Netw Open. 2020;3(4):e203969.
- Muddasani S, Fleischer AB. United States systemic psoriasis treatments: increases in the use of biologic agents and plateau of methotrexate and oral small molecule inhibitors. J Dermatolog Treat. 2020;1–3. doi:10.1080/09546634.2020.1729951
- Singh P, Silverberg JI. Real-world trends in biologic, oral systemic, and phototherapy in US patients with psoriasis or psoriatic arthritis. J Am Acad Dermatol. 2020;83(1):256–257.
- Diamond HS, Goldberg E, Janosky JE. The effect of full-time faculty hospitalists on the efficiency of care at a community teaching hospital. Ann Intern Med. 1998;129(3):197–203.
- Dunn A, Grosse SD, Zuvekas SH. Adjusting health expenditures for inflation: a review of measures for health services research in the United States. Health Serv Res. 2018;53(1):175–196.
- Schondelmeyer S, Purvis L. Trends in Retail Prices of Prescription Drugs Widely Used by Older Americans, 2006 to 2013. AARP Public Policy Institute. [cited 2020 Oct 4]. Available from: https://www.aarp.org/content/dam/aarp/ppi/2016-02/RX-Price-Watch-Trends-in-Retail-Prices-Prescription-Drugs-Widely-Used-by-Older-Americans.pdf.
- Barlas S. Are specialty drug prices destroying insurers and hurting consumers? P T. 2014;39(8):563–566.
- Cubanski J, Neuman T, True S, et al. What’s the latest on medicare drug price negotiations? KFF. 2019. [Published 2019 Oct 17; cited 2020 Sept 20]. Available from: https://www.kff.org/medicare/issue-brief/whats-the-latest-on-medicare-drug-price-negotiations/
- Yazdany J, Dudley RA, Chen R, et al. Coverage for high-cost specialty drugs for rheumatoid arthritis in medicare part D. Arthritis Rheumatol. 2015;67(6):1474–1480.
- Trish E, Xu J, Joyce G. Medicare beneficiaries face growing out-of-pocket burden for specialty drugs while in catastrophic coverage phase. Health Aff (Millwood). 2016;35(9):1564–1571.
- Dusetzina SB, Huskamp HA, Keating NL. Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in medicare part D, 2010 to 2019. JAMA. 2019;321(20):2025–2027.
- Department of Health and Human Services. High-price drugs are increasing federal payments for medicare part D catastrophic coverage. [cited 2020 Sept 20]. Available from: https://www.oversight.gov/sites/default/files/oig-reports/oei-02-16-00270.pdf.
- Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–269.